Sept. 30–Oct. 1, 2021 • San Diego
View Schedule • Registration Rates • Register Now
ORGANIZERS
- Elizabeth Budde, MD, PhD – City of Hope
- Daniel S. Chen, MD, PhD – IGM Biosciences, Inc.
- James L. Gulley, MD, PhD, FACP – National Cancer Institute
Overview
The Society for Immunotherapy of Cancer (SITC) invites you to attend the workshop, Bispecific T cell Engagers. This SITC workshop will focus on T cell engager biology and therapeutic strategies including target selection, therapeutic engineering and design features, cytotoxicity vs cytokine release, impact of the tumor microenvironment, and advances in conditionally-active binding.
Additionally, considerations related to dosing, schedule, sequencing and combination approaches for optimizing both endogenous and synthetic immunity will be discussed.
Target Audience
- Basic, translational and clinical researchers from academic, industry, or government settings with an interest in developing, validating and applying T cell engager therapies for cancer treatment.
Learning Objectives
- Compare and contrast cancer immunotherapy approaches employing endogenous or synthetic immunity.
- Describe the biological and engineering considerations for development of T cell engagers.
- Outline current clinical application of T cell engagers and identify challenges with their use in cancer immunotherapy.